High-Strength Wegovy; Aldosteronism Outcome Definitions; Insulin Unit Price Down 42%

Patients treated with semaglutide 7.2 mg achieved a 20.7% weight loss after 72 weeks compared with a reduction of 17.5% with semaglutide 2.4 mg (Wegovy) and 2.4% with placebo, results from the phase IIIb STEP UP trial showed.

Eli Lilly has its sights set on approval of orforglipron, a once-daily oral GLP-1 receptor agonist for weight loss, by early 2026. (Becker’s Hospital Review)

An international panel of 31 experts developed definitions for complete, partial, or absent biochemical and clinical outcomes after medical treatment for primary aldosteronism. (Lancet Diabetes & Endocrinology)

Unadjusted total calcium measurements are the best and most practical alternative to ionized calcium measurements in most clinical settings, a cross-sectional study reported. (JAMA Network Open)

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 — the lowest average recorded in a decade, according to a GoodRx report.

A dietitian defended ultraprocessed foods in Slate.

Here’s how President Trump’s Greenland plan may affect access to popular medications like some GLP-1 receptor agonists. (New York Times)

A meta-analysis turned up no evidence that use of GLP-1 receptor agonists was tied to an increased risk of thyroid cancer over a median follow-up of up to 3 years. (Thyroid)

California Gov. Gavin Newsom’s (D) plan to produce cheap, generic insulin is far behind schedule, industry experts said. (CalMatters)

In related news, a federal law that made companies reduce the price of insulin resulted in smaller discounts for low-income clinics. (New York Times)

Data from continuous glucose monitoring predicted microvascular complications in patients with type 1 diabetes. (Diabetes Technology & Therapeutics)

Excess weight gain in the first trimester of pregnancy was associated with fetal fat accumulation, a prospective cohort study showed. (American Journal of Clinical Nutrition)

A large study of South Korean women found that those who experienced menopause before age 45 had a higher risk for type 2 diabetes compared with those at ages 50 and older. (JAMA Network Open)

Please enable JavaScript to view the

comments powered by Disqus.